Multisensory Room Therapy for Stress and Sensory Regulation in Children With Autism and Their Caregivers

November 13, 2026 updated by: SERGIO MONTERO NAVARRO

Multidimensional Study of Child and Parental Stress in Autism Spectrum Disorder After a Multisensory Intervention: Biomarkers, Sensory Responses and Clinical Assessment. A Randomised Controlled Trial

The goal of this clinical trial is to learn whether therapy in a multisensory room improves sensory processing, behavioural and attentional regulation and stress in children aged 3 to 12 years with autism spectrum disorder (support level 2-3), and whether it reduces stress in their main caregivers. The main question it aims to answer is: does sensory processing (Sensory Profile 2) change more after 8 weeks of multisensory room therapy than after 8 weeks of standard behavioural therapy? Researchers will also compare executive function, attention and behaviour, parental stress, and stress-related biomarkers in saliva (cortisol, oxytocin and inflammatory interleukins). They will also record physiological stress signals in caregivers (heart rate, skin conductance, breathing and temperature).

Sixty children will be randomly assigned to one of two groups. Children in the first group will receive two individual 45-minute multisensory room sessions per week for 8 weeks. Children in the second group will receive standard behavioural therapy with psychology and speech therapy, without multisensory stimulation. Caregivers will complete questionnaires and give saliva samples before and after the 8-week programme.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background. Sensory processing differences are highly prevalent in autism spectrum disorder (ASD) and are associated with anxiety, emotional dysregulation and lower adaptive functioning. Children with ASD show atypical activation of the hypothalamic-pituitary-adrenal axis and elevated pro-inflammatory cytokines. Parents of children with ASD report high parenting stress. Multisensory environments (Snoezelen®) are widely used to support self-regulation, but controlled trials with objective outcomes are scarce.

Design. Randomised, controlled, parallel-group trial with pre-post assessment. Families with a child aged 3-12 years with ASD (support level 2-3) attending the Centre de Teràpia Interfamiliar (Elche, Spain) are randomised 1:1. Randomisation is stratified by age, sex and the primary outcome, in blocks of two, and the sequence is concealed. Outcome assessors are blinded to group allocation; therapists cannot be blinded.

Interventions. Multisensory group: 16 individual 45-minute sessions (2 per week for 8 weeks) in a multisensory room, delivered by occupational therapists trained in multisensory stimulation in ASD. Each session follows a semi-structured protocol: welcome and adaptation (5 min); guided sensory regulation with graded visual, auditory, tactile, vestibular and proprioceptive stimuli (15-20 min); active participation and control of the environment (10-15 min); and closure with return to calm (5 min). Control group: 45-minute sessions of standard behavioural therapy with psychology and speech therapy, under standard lighting, without therapeutic multisensory stimuli and with the same therapist presence.

Assessments. Baseline (T0): child saliva biomarkers; caregiver-reported Sensory Profile 2, BRIEF-P/BRIEF-2, Conners scales and PSI-SF; caregiver saliva and hair biomarkers; and caregiver physiological recording (BIOPAC MP36R). During the intervention (T1): child saliva before and after each session, and a structured observational self-regulation record after each session. After 8 weeks (T2): caregiver-reported scales, caregiver biomarkers and physiological recording. Salivary cortisol, oxytocin, IL-6, IL-1β, IL-17A and TNF-α are analysed by ELISA at Universidad CEU Cardenal Herrera.

Setting and data. The study is conducted at the Centre de Teràpia Interfamiliar (Elche, Spain) in collaboration with the Neurobiology research group of Universidad CEU Cardenal Herrera. Data are pseudonymised and handled in accordance with the GDPR and Spanish Organic Law 3/2018.

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 12 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria (children):

  • Clinical diagnosis of autism spectrum disorder, support level 2 or 3 (DSM-5).
  • Age 3 to 12 years.
  • Attending and registered at the Centre de Teràpia Interfamiliar.
  • Stable therapeutic and pharmacological treatment during the study period.
  • Able to tolerate entering and remaining in the multisensory room.
  • Written informed consent from parents or legal guardians.

Exclusion Criteria (children):

  • Uncontrolled epilepsy.
  • Recent changes in medication.
  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the intervention.
  • Persistent refusal of, or inability to adapt to, the multisensory room.

Inclusion Criteria (caregivers):

  • Adult (18 years or older) main caregiver of an enrolled child.
  • Sufficient cognitive capacity to understand the informed consent.

Exclusion Criteria (caregivers):

  • Acute illness at the time of assessment.
  • Severe motor or sensory disability preventing participation in the assessments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Multisensory room therapy

Children with ASD receive 8 individual 45-minute sessions (1 per week for 8 weeks) in a multisensory room. Their caregivers complete assessments and provide biological samples.

Semi-structured individual session in a multisensory (Snoezelen®) room delivered by occupational therapists trained in multisensory stimulation in ASD: (1) welcome and adaptation, 5 min, with dim light and no loud sounds; (2) guided sensory regulation, 15-20 min, with graded visual, auditory, tactile, vestibular and proprioceptive stimuli adjusted to the child's profile; (3) active participation and control of the environment, 10-15 min, in which the child chooses or modulates stimuli; (4) closure and return to calm, 5 min. Two sessions per week for 8 weeks.

Other Names:
  • Snoezelen; Multisensory environment (MSE)
Active Comparator: Standard behavioural therapy

Children with ASD receive 45-minute sessions of standard behavioural therapy (psychology and speech therapy) without multisensory stimulation, over the same 8-week period. Their caregivers complete the same assessments.

45-minute session with psychology and speech therapy addressing children with ASD support level 2-3, under standard lighting, without therapeutic multisensory stimuli, and with the same therapist presence as the experimental arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in sensory hyper-reactivity (Sensory Profile 2, Sensitivity quadrant)
Time Frame: Baseline and week 8

Sensory Profile 2 - Child form, completed by the main caregiver. Raw score of the Sensitivity quadrant (19 items, each rated from 1 = almost never to 5 = almost always; range 19-95). Higher scores indicate more frequent sensory hyper-reactivity (worse outcome).

Baseline and week 8

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in executive function (Behavior Rating Inventory of Executive Function, BRIEF-P / BRIEF-2)
Time Frame: Baseline and week 8

Behavior Rating Inventory of Executive Function - Preschool Version (BRIEF-P, ages 3-5) or BRIEF-2 parent form (ages 5-12), completed by the main caregiver. Global Executive Composite raw score (63 items rated 1-3; range 63-189). Higher scores indicate greater executive dysfunction (worse outcome).

Baseline and week 8
Change in emotional and behavioural problems (SENA, Global Problems Index)
Time Frame: Baseline and week 8

Child and Adolescent Assessment System (SENA), family-report form for ages 3-6 or 6-12, completed by the main caregiver. Global Problems Index, T-score (normative mean 50, SD 10; range of risk 65-69; significative range of risk: >70). Higher scores indicate more emotional and behavioural problems (worse outcome).

Baseline and week 8
Parenting stress (PSI-SF)
Time Frame: Baseline and week 8

PSI-SF is a 36-item, self-report measure of parenting stress. It includes three subscales: Parental Distress (PD; e.g, "I feel trapped by my responsibilities as a parent", "I feel lonely and without friends"), Parent-Child Dysfunctional Interaction (PCDI; e.g, "Sometimes I feel my child doesn't like me and doesn't want to be close to me", "When I do things for my child I get the feeling that my efforts are not appreciated" ), and Difficult Child (DC; e.g, "My child makes more demands on me than most children", "My child gets upset easily over the smallest thing"). Each subscale consists of 12 items rated from 1 (strongly disagree) to 5 (strongly agree), with subscales scores ranging from 12 to 60. A Total score is calculated by summing the three subscales scores, ranging from 36 to 180. Scores of 90 or above may indicate a clinical level of stress.

Baseline and week 8
Child salivary cortisol (ng/mL)
Time Frame: Baseline and before/after each session, weeks 1-8

ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of cortisol: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

Baseline and before/after each session, weeks 1-8
Child salivary oxytocin (pg/mL)
Time Frame: Baseline and before/after each session, weeks 1-8

ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen. Quantification of oxytocin: RT-2100C microplate reader, which is a general-purpose microprocessor-controlled photometric system designed to read and calculate biomarker assay results (optic ivymen system)

Baseline and before/after each session, weeks 1-8
Child salivary pro-inflammatory cytokines
Time Frame: Baseline and before/after each session, weeks 1-8

Salivary IL-6, IL-1β, IL-17A and TNF-α (pg/mL, ELISA).

Baseline and before/after each session, weeks 1-8
Caregiver stress biomarkers - Salivary cortisol (ng/mL)
Time Frame: Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - oxytocin (pg/mL)
Time Frame: Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - IL-6, IL-1β, IL-17A and TNF-α (pg/mL) (ELISA)
Time Frame: Baseline and week 8
Baseline and week 8
Caregiver stress biomarkers - hair cortisol (pg/mg)
Time Frame: Baseline and week 8
Baseline and week 8
In-session self-regulation (observational record)
Time Frame: After each session, weeks 1-8

Therapist-rated 8-item record (0-3 per item; total 0-24). Higher scores indicate greater self-regulation difficulty.

After each session, weeks 1-8
Heart rate and heart rate variability (LF, HF, LF/HF ratio). BIOPAC MP36R device
Time Frame: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Galvanic response by means of Skin conductance (SC). micro-siemens or micro-omhios. BIOPAC MP36R device
Time Frame: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Breathing rate (breaths per minute). BIOPAC MP36R device
Time Frame: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8
Skin temperature (ºC). BIOPAC MP36R device
Time Frame: Baseline and week 8

During a recording of about 30 minutes

Baseline and week 8

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse events
Time Frame: Weeks 1-8

Number of children with behavioural crises, sensory overload requiring session interruption, or other adverse events, by group.

Weeks 1-8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 3, 2027

Primary Completion (Estimated)

March 30, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

November 4, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CEEI26/863

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Coded data may be shared only for purposes consistent with the study and under confidentiality guarantees; no international transfers are planned.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.